Dr. Reddy’s Laboratories shares jump over 1% as European Commission approves biosimilar AVT03

[hfe_template id='11223'] [ad_1]
Dr. Reddy’s Laboratories shares jumped 1.5% to their day’s low of Rs 1242.90 on the BSE on Tuesday, November 25, after the company announced that the European Commission (EC) has granted marketing authorization for AVT03, a proposed biosimilar of Prolia and Xgeva.

In an official statement dated November 24, the company said the authorization covers all EU Member States as well as countries within the European Economic Area, including Iceland, Liechtenstein and Norway. AVT03 (denosumab) is indicated for conditions such as osteoporosis in postmenopausal women and bone-related complications arising from advanced cancers, based on the referenced products Prolia and Xgeva.


The approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in September 2025.

According to the company, the decision was supported by analytical comparisons, pharmacokinetic and pharmacodynamic assessments, and outcomes from a confirmatory clinical trial.


Dr. Reddy’s entered into a licensing and supply agreement with Alvotech in May 2024 for AVT03. Under this arrangement, Alvotech will manufacture the product, while Dr. Reddy’s will handle registration and commercialization across key markets, including the U.S. and Europe.

Commercialization rights will be exclusive to Dr. Reddy’s in the U.S. and semi-exclusive in Europe and the UK. Following approval, the biosimilar will be marketed under the brands Acyvbra for a 60 mg/mL pre-filled syringe formulation and Xbonzy for a 70 mg/mL vial injection.AVT03 is a human monoclonal IgG2 antibody and biosimilar candidate to Prolia and Xgeva, which are both denosumab but in different presentations. Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction.Also read: Ashish Kacholia, Anil Goel, Mukul Agrawal & Ashish Dhawan lose big as portfolios crash up to 29%

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
[ad_2] Source link https://mrgaga.in/dr-reddys-laboratories-shares-jump-over-1-as-european-commission-approves-biosimilar-avt03/?feed_id=52707&_unique_id=69256050d70d0

Comments

Post a Comment

Popular posts from this blog

India VIX jumps 100% in one month. Could fear levels take Nifty further down?

Image
[hfe_template id='11223'] [ad_1] Volatility in Indian equity markets has surged sharply over the past month, with the India VIX nearly doubling as geopolitical tensions and global uncertainty triggered aggressive selling in equities. India VIX, often referred to as the market’s fear gauge, has jumped close to 100% over the past month, reflecting growing nervousness among investors. The spike has coincided with a sharp correction in the broader market, with the Nifty 50 declining about 8% during the same period. The escalation of tensions involving the United States, Israel and Iran has intensified market anxiety in recent days, pushing crude oil prices sharply higher and triggering a global risk-off sentiment. However, analysts note that volatility had already been building even before the conflict escalated, reflecting broader concerns around global growth, foreign capital outflows and stretched valuations in equities. The heightened uncertainty translated into a sharp ...
Read more

Can Sensex, Nifty snap 2-day fall on Monday? 7 factors that could decide market mood this week

Image
[hfe_template id='11223'] [ad_1] Benchmark indices Sensex and Nifty ended the week on a bearish note, closing over a percent lower each as a deepening selloff in IT stocks rattled investor sentiment amid mounting fears of AI-led disruption. Further, stronger-than-expected jobs data for January dampened hopes of a US Fed interest rate cut. Here are 7 factors that could decide market action in the coming week: 1.) Infosys, Wipro ADRs rebound - After a brutal two-day selloff that saw Infosys and Wipro ADRs plunge as much as 14.5%, Friday’s session brought a much-needed breather. Bargain hunting kicked in at lower levels, sparking a sharp rebound as Infosys climbed 3% while Wipro gained 4%—helping both stocks close the week on a far stronger note. International brokerage firm JP Morgan has a message for panic-stricken investors: IT services firms are the indispensable "plumbers of the tech world" and their dividend yields have now hit levels last seen only during ...
Read more

Waaree Energies shares in focus after Q4 profit rises 34% to Rs 619 crore, revenue up 36%

Image
[hfe_template id='11223'] [ad_1] Waaree Energies shares will be in focus on Wednesday after the solar panel maker reported a strong Q4 performance, with net profit rising 34.1% year-on-year (YoY) to Rs 618.9 crore for the quarter ended March 31, 2025. In the same quarter last year, the company had reported a profit of Rs 461.5 crore. Revenue from operations jumped 36.4% to Rs 4,003.9 crore, up from Rs 2,935.8 crore in the year-ago period, according to the company’s regulatory filing. EBITDA more than doubled to Rs 922.6 crore in Q4 FY25, up 120.6% from Rs 418.3 crore in the same quarter last year. The EBITDA margin improved to 23% from 14.3% a year ago. The company produced 2.06 GW of solar modules in the fourth quarter, up from 1.35 GW in the same period last year. For the full year, module production reached 7.13 GW, compared to 4.77 GW in FY24. For the full financial year FY25, revenue rose 27.62% YoY to Rs 14,846.06 crore. Profit after tax more than doubled to Rs 1,9...
Read more